JPMorgan analyst Allen Gong raised the firm’s price target on TransMedics (TMDX) to $149 from $114 and keeps a Neutral rating on the shares. The firm says the company’s inline fiscal Q3 results will likely disappoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $160 from $140 at Piper Sandler
- TransMedics price target raised to $152 from $148 at Canaccord
- Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating
- Closing Bell Movers: First Solar down 12% on earnings miss
- TransMedics reports Q4 EPS $2.62 with items, consensus 37c